Highly hypofractionated schedules for localized prostate cancer: Recommendations of the GETUG radiation oncology group

Ariane Lapierre; Christophe Hennequin; Amandine Beneux; Sarah Belhomme; Nicolas Benziane Ouaritini; Marie-Claude Biston; Gilles Crehange; Renaud de Crevoisier; Jean-Luc Dumas; Maher Fawzi; Albert Lisbona; David Pasquier; Sandra Pelissier; Pierre Graff-Cailleaud; Pascal Pommier; Paul Sargos; Jean-Marc Simon; Stéphane Supiot; Florence Tantot; Olivier Chapet

doi:10.1016/j.critrevonc.2022.103661

Highly hypofractionated schedules for localized prostate cancer: Recommendations of the GETUG radiation oncology group

Crit Rev Oncol Hematol. 2022 May:173:103661. doi: 10.1016/j.critrevonc.2022.103661. Epub 2022 Mar 25.

Authors

Ariane Lapierre¹, Christophe Hennequin², Amandine Beneux³, Sarah Belhomme⁴, Nicolas Benziane Ouaritini⁵, Marie-Claude Biston⁶, Gilles Crehange⁷, Renaud de Crevoisier⁸, Jean-Luc Dumas⁹, Maher Fawzi¹⁰, Albert Lisbona¹¹, David Pasquier¹², Sandra Pelissier¹³, Pierre Graff-Cailleaud¹⁴, Pascal Pommier¹⁵, Paul Sargos¹⁶, Jean-Marc Simon¹⁷, Stéphane Supiot¹⁸, Florence Tantot¹³, Olivier Chapet¹⁹

Affiliations

¹ Département of de radiothérapie oncologie, centre hospitalier universitaire Lyon Sud, 165, chemin du Grand-Revoyet, 69495 Pierre-Bénite, France; Université de Lyon, 69000 Lyon, France.
² Department of Radiation Oncology, Hôpital Saint-Louis, 75475 Paris, France.
³ Service de Physique Médicale et de Radioprotection, centre hospitalier universitaire Lyon Sud, 165, chemin du Grand-Revoyet, 69495 Pierre-Bénite, France.
⁴ Radiation Oncology Department, Bergonie Institute, 229, cours de l'Argonne, 33076 Bordeaux Cedex, France.
⁵ Radiation Oncology Department, Bergonie Institute, 229, cours de l'Argonne, 33076 Bordeaux Cedex, France. Electronic address: [email protected].
⁶ Léon Bérard Cancer Center, University of Lyon, France; Université de Lyon, CREATIS, CNRS UMR5220, Inserm, U1044 INSA, Lyon, France.
⁷ Département de radiothérapie oncologique, institut Curie, 26, rue d'Ulm, 75005 Paris, France.
⁸ Département de Radiothérapie, Centre Eugène Marquis, Rennes, France.
⁹ Institut Curie, Radiotherapy department / Medical physics, 26 rue d'Ulm, 75005 cedex Paris, France.
¹⁰ Institut Curie, Site Saint Cloud, Service de Radiotherapie, 35, rue Dailly, 92210 Saint Cloud, France.
¹¹ Medical Physics Department Institut de Cancérologie de l'Ouest, Bd J. Monod, 44805 Saint Herblain, France.
¹² Academic Department of Radiation Oncology, Centre Oscar Lambret, Lille; CRIStAL UMR, 9189 Lille, France.
¹³ GETUG Group, Unicancer, Paris, France.
¹⁴ University Institute of Cancer Toulouse-Oncopôle, Toulouse, France.
¹⁵ Radiotherapy Department, Centre Léon Bérard, Lyon, France.
¹⁶ Radiation Oncology Department, Bergonie Institute, Bordeaux, France.
¹⁷ Department of Radiotherapy, Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière University Hospital, Paris, France.
¹⁸ Department of Radiation Oncology, Institut de Cancérologie de l'Ouest, Nantes, St-Herblain, France.
¹⁹ Département of de radiothérapie oncologie, centre hospitalier universitaire Lyon Sud, 165, chemin du Grand-Revoyet, 69495 Pierre-Bénite, France; Université de Lyon, 69000 Lyon, France. Electronic address: [email protected].

PMID: 35341986
DOI: 10.1016/j.critrevonc.2022.103661

Abstract

Stereotactic body radiotherapy (SBRT) has become treatment option for localized prostate cancer but the evidence base remains incomplete. Several clinical studies, both prospective and retrospective, have been published. However, treatment techniques, target volumes and dose constraints lack consistency between studies. Based on the current available literature, the French Genito-Urinary Group (GETUG) suggests that.

Keywords: Prostatic Neoplasms; Prostatic Neoplasms /radiotherapy; Radiosurgery/methods; Radiotherapy Dosage.

Publication types

Review

MeSH terms

Humans
Male
Prospective Studies
Prostatic Neoplasms* / radiotherapy
Prostatic Neoplasms* / surgery
Radiosurgery* / methods
Retrospective Studies